DLBCL Educational Pamphlet- Learn more about diffuse large B-cell lymphoma (DLBCL), the most common and aggressive form of B-cell non-Hodgkin’s lymphoma
Leukemia & Lymphoma
Lymphoma is the most common type of blood cancer, with over 400,000 people diagnosed around the world each year. It begins in a certain type of cell of the immune system (lymphocytes, or white blood cells) and can be divided into two main categories – Hodgkin lymphoma, and Non-Hodgkin lymphoma (NHL).
NHL is the more common of the two and can be further categorised as indolent (slow growing) or aggressive (fast growing), depending on the speed with which the cancer grows. Follicular lymphoma is the most common indolent form of the disease and diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form.
Leukaemia is the second most common form of blood cancer, with over 300,000 people diagnosed globally each year. The type of leukaemia that a person has is dependent on which type of blood cell – white or red – becomes cancerous.
The four main types of leukaemia include acute lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML), and chronic myeloid leukaemia (CML).
Learn more about the latest advances in Roche lymphoma and leukaemia research.
Final Results From the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab + Bendamustine in Previously Untreated Patients With Chronic Lymphocytic Leukemia (NCT02320487).
The Phase IIIb GREEN safety study (NCT01905943) compared obinutuzumab alone or combined with chemotherapy in previously untreated (fit or unfit) or relapsed/refractory patients with chronic lymphocytic leukemia: final analysis results are presented.
This analysis reports the health-related quality of life data over 3 years from the Phase II GIBB study (NCT02320487), which investigated obinutuzumab in combination with bendamustine in patients with previously untreated chronic lymphocytic leukemia.
This is an ongoing multicenter phase I dose escalation trial investigating the safety, tolerability, pharmacokinetics (PK), biomarkers and antitumor activity of CD20-TCB in patients with heavily pre-treated NHL. Safety and efficacy data are presented
This analysis explores the clinical impact of major somatic mutations and cytogenetic high-risk features on outcome in patients treated with venetoclax▼-rituximab and bendamustine-rituximab in MURANO (NCT02005471). Prevalence of all key mutated genes in CLL will be presented.
The presentation reports the safety and efficacy results from the interim analysis of a Phase I/II study of polatuzumab vedotin + obinutuzumab + lenalidomide in patients with relapsed/refractory follicular lymphoma. Interim safety and efficacy data are presented.
In the phase III GALLIUM trial (NCT01332968), we evaluated the performance and treatment-dependence of two high-risk follicular lymphoma models in patients with follicular lymphoma who were treated with obinutuzumab- or rituximab-based immunochemotherapy, plus maintenance. Data presented highlight the challenges of building high-risk signatures for patients independent of treatment.
The phase 3 MabCute trial (NCT01461928) evaluated the efficacy and safety of prolonged R-SC maintenance after standard R-SC-based induction and maintenance in relapsed or refractory patients with indolent non-Hodgkin lymphoma. Primary analysis results are presented.
Biopsy sample data from the phase III GOYA trial (NCT01287741) and FMI Clinical Database were examined using a clinically available, targeted comprehensive genomic profiling (CGP) platform to evaluate the interplay of neoantigen burden and specific neoantigens to provide prognostic insight into DLBCL.
The presentation reports the safety and efficacy results from the interim analysis of a phase I/II study of polatuzumab vedotin + obinutuzumab + lenalidomide in patients with relapsed/refractory follicular lymphoma. Interim safety and efficacy data are presented.
POLARIX (NCT03274492) will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes of 1.8mg/kg pola + chemoimmunotherapy (R-CHP) compared with SOC chemoimmunotherapy (R-CHOP) in previously untreated patients with intermediate- to high-risk CD20-positive DLBCL. This Trial in Progress poster presents the study design, key inclusion/exclusion criteria, study endpoints and treatment schedule.
MIRROS is a randomized Phase III trial investigating the effects of idasanutlin (MDM2 antagonist) in combination with cytarabine versus placebo in combination with cytarabine in patients with relapsed or refractory AML. This Trial in Progress poster presents the MIRROS study design, including eligibility criteria, study endpoints, the futility interim analysis and enrollment status.